Skip to main content
SpringerLink
Log in

Selective serotonin reuptake inhibitors use and the risk of hepatocellular carcinoma: a systematic review and dose–response analysis of cohort studies with one million participants

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL (2017) Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget 8(18):30464–30470. https://doi.org/10.18632/oncotarget.12826

    Article  PubMed  Google Scholar 

  2. Bhagavathula AS, Woolf B, Rahmani J, Vidyasagar K, Tesfaye W (2022) Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose–response analysis of cohort studies with one million participants. Eur J Clin Pharmacol 1–9

  3. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Social and Clinical Pharmacy, Faculty of Pharmacy at Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

    Akshaya Srikanth Bhagavathula

  2. Department of Psychological Sciences, University of Bristol, Bristol, BS8 1TH, UK

    Benjamin Woolf

  3. Department of Community Nutrition, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Jamal Rahmani

  4. Department of Pharmaceutical Sciences, University College of Pharmaceutical Sciences, Hanamkonda, 506009, Telangana, India

    Kota Vidyasagar

  5. Health Research Institute, University of Canberra, Canberra, Australia

    Wubshet Tesfaye

  6. Sydney Pharmacy School, The University of Sydney, Camperdown, Sydney, NSW, Australia

    Wubshet Tesfaye

Authors
  1. Akshaya Srikanth Bhagavathula
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Woolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jamal Rahmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kota Vidyasagar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wubshet Tesfaye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Akshaya Srikanth Bhagavathula or Wubshet Tesfaye.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhagavathula, A.S., Woolf, B., Rahmani, J. et al. Selective serotonin reuptake inhibitors use and the risk of hepatocellular carcinoma: a systematic review and dose–response analysis of cohort studies with one million participants. Eur J Clin Pharmacol 78, 1199–1200 (2022). https://doi.org/10.1007/s00228-022-03309-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-022-03309-y

Search

Navigation